Directly to content
  1. Publishing |
  2. Search |
  3. Browse |
  4. Recent items rss |
  5. Open Access |
  6. Jur. Issues |
  7. DeutschClear Cookie - decide language by browser settings

Prostate bed irradiation with alternative radio-oncological approaches (PAROS) - a prospective, multicenter and randomized phase III trial

Koerber, Stefan A. ; Katayama, Sonja ; Sander, Anja ; Jaekel, Cornelia ; Haefner, Matthias F. ; Debus, Juergen ; Herfarth, Klaus

In: Radiation Oncology, 14 (2019), Nr. 122. pp. 1-6. ISSN 1748-717X

[img] PDF, English - main document
Download (714kB) | Lizenz: Creative Commons LizenzvertragProstate bed irradiation with alternative radio-oncological approaches (PAROS) - a prospective, multicenter and randomized phase III trial by Koerber, Stefan A. ; Katayama, Sonja ; Sander, Anja ; Jaekel, Cornelia ; Haefner, Matthias F. ; Debus, Juergen ; Herfarth, Klaus underlies the terms of Creative Commons Attribution 4.0

Citation of documents: Please do not cite the URL that is displayed in your browser location input, instead use the DOI, URN or the persistent URL below, as we can guarantee their long-time accessibility.

Abstract

Background: For patients with treatment-naïve carcinoma of the prostate, hypofractionated irradiation becomes more and more popular. Due to the low α/β value of prostate cancer, increased single dose leading to a shortened treatment period seems to be safe and feasible. However, reliable data is lacking for post-prostatectomy patients so far. Further, the role of proton therapy is still under debate. Two prospective phase II trials with both, hypofractionated photon and proton therapy, provided promising results.

Methods/design: The PAROS trial is a prospective, multicenter and randomized phase III trial for men with localized prostate carcinoma after surgery. Post-prostatectomy patients will be randomized to either normofractionated radiotherapy (nRT) with photons (70.0/ 2.0 Gy), or hypofractionated radiotherapy (hRT) with photons (57.0/ 3.0 Gy) or hRT with protons (57.0/ 3.0 Gy relative biological effectiveness [RBE]). Block randomization is stratified by Gleason Score (≤ 7 vs. > 7) and treatment indication (adjuvant vs. salvage). The trial is planned to enroll 897 patients. The primary objective is to show an improvement in the bowel-score according to EORTC QLQ-PR25 after proton therapy compared to photon irradiation (week 12 vs. baseline). Secondary aims are non-inferiority of hRT compared to nRT with regard to biochemical progression-free survival (bPFS), overall survival (OS), quality of life and toxicity.

Discussion: The present study aims to evaluate the role of hypofractionated radiotherapy to the prostate bed with photons and protons leading to significant impact on future management of operated men with prostate cancer.

Trial registration: Deutsches Register klinischer Studien DRKS00015231; registered 27 September 2018.

Item Type: Article
Journal or Publication Title: Radiation Oncology
Volume: 14
Number: 122
Publisher: BioMed Central
Place of Publication: London
Date Deposited: 13 Aug 2019 10:32
Date: 2019
ISSN: 1748-717X
Page Range: pp. 1-6
Faculties / Institutes: Service facilities > German Cancer Research Center (DKFZ)
Medizinische Fakultät Heidelberg > Institut für Medizinische Biometrie und Informatik
Medizinische Fakultät Heidelberg > Heidelberg Ion-Beam Therapy Center (HIT)
Subjects: 610 Medical sciences Medicine
Uncontrolled Keywords: Prostate cancer, Prostate bed, Hypofractionation, Protons, Radiotherapy, Salvage
About | FAQ | Contact | Imprint |
OA-LogoDINI certificate 2013Logo der Open-Archives-Initiative